Abstract Objective To study the clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura. Methods Children with abdominal Henoch-Schönlein purpura who needed nutritional support were enrolled and stratified according to age, sex and the severity of disease, and were randomly divided into a control group (n=118) and an enriched nutritional support group (n=107). The control group was given nutritional support without using alanyl-glutamine, while the enriched nutritional support group was given alanyl-glutamine-enriched nutritional support. Intravenous steroids were used according to the severity of disease in both groups. Other therapies were the same in the two groups. The two groups were compared in terms of the length of hospital stay, the rate and duration of use of intravenous steroids, the recurrence rate of symptoms during hospitalization, the rate of total parenteral nutrition (TPN), the rate of weight loss and the rate of fasting for more than 5 days. All patients were followed up for 3 months after discharge to monitor the recurrence of symptoms. Results There were no significant differences in the length of hospital stay, the rate of TPN and the rate of fasting for more than 5 days between the two groups (P > 0.05). Compared with the enriched nutritional support group, the control group showed significant increases in the rate and duration of use of intravenous steroids, the recurrence rate of symptoms and the rate of weight loss (P < 0.05). After the 3-month follow-up, all the children resumed normal diet, and the recurrence rate of digestive symptoms was less than 20% in each group. Abdominal pain was the most common symptom (83.33%, 30/36), followed by vomiting and abdominal distention. No digestive hemorrhage was observed. All the symptoms were relieved after symptomatic treatment. No significant difference was found between the two groups in the recurrence rate of digestive symptoms (P=0.693). Conclusions Alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura can reduce the use of intravenous steroids and weight loss, but without impact on the length of hospital stay and post-discharge recurrence.
XIONG Li-Jing,SHANG Li-Hong,OU Xiao-Qin et al. Clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura[J]. CJCP, 2019, 21(2): 168-171.
XIONG Li-Jing,SHANG Li-Hong,OU Xiao-Qin et al. Clinical effect of alanyl-glutamine-enriched nutritional support in the treatment of children with abdominal Henoch-Schönlein purpura[J]. CJCP, 2019, 21(2): 168-171.
Dao DT, Anez-Bustillos L, Cho BS, et al. Assessment of micronutrient status in critically ill children:challenges and opportunities[J]. Nutrients, 2017, 9(11):E1185.
[7]
Oldani M, Sandini M, Nespoli L, et al. Glutamine supplementation in intensive care patients:a meta-analysis of randomized clinical trials[J]. Medicine (Baltimore), 2015, 94(31):e1319.
[8]
van Zanten AR, Dhaliwal R, Garrel D, et al. Enteral glutamine supplementation in critically ill patients:a systematic review and meta-analysis[J]. Crit Care, 2015, 19:294.
Wang X, Pierre JF, Heneghan AF, et al. Glutamine improves innate immunity and prevents bacterial enteroinvasion during parenteral nutrition[J]. JPEN J Parenter Enteral Nutr, 2015, 39(6):688-697.
[15]
Jiang Q, Chen J, Liu S, et al. l-Glutamine attenuates apoptosis induced by endoplasmic reticulum stress by activating the IRE1α-XBP1 axis in IPEC-J2:a novel mechanism of l-glutamine in promoting intestinal health[J]. Int J Mol Sci, 2017, 18(12):E2617.
[16]
Kim MH, Kim H. The roles of glutamine in the intestine and its implication in intestinal diseases[J]. Int J Mol Sci, 2017, 18(5):E1051.
[17]
Alpers DH. Glutamine:do the data support the cause for glutamine supplementation in humans?[J]. Gastroenterology, 2006, 130(2 Suppl 1):S106-S116.
[18]
Mori M, Smedberg M, Klaude M, et al. A tracer bolus method for investigating glutamine linetics in humans[J]. PLoS One, 2014, 9(5):e96601.
